{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:46:55Z","timestamp":1793875615219,"version":"4.6.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T00:00:00Z","timestamp":1610236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.contraception.2021.01.001","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T16:56:06Z","timestamp":1610297766000},"page":"213-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5529-0063","authenticated-orcid":false,"given":"Christine","family":"Klipping","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Duijkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Mawet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Bastidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Foidart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2021.01.001_bib0001","first-page":"299","article-title":"Pharmacological profile of estrogens in oral contraception","volume":"63","author":"Bitzer","year":"2011","journal-title":"Minerva Ginecol"},{"key":"10.1016\/j.contraception.2021.01.001_bib0002","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/09513590.2012.662547","article-title":"An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate\/dienogest","volume":"28","author":"Fruzzetti","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.contraception.2021.01.001_bib0003","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/13625187.2011.604450","article-title":"Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism","volume":"16","author":"Agren","year":"2011","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2021.01.001_bib0004","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0010-7824(02)00537-1","article-title":"A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism","volume":"67","author":"Gaspard","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2021.01.001_bib0005","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/17425255.2016.1190832","article-title":"Metabolic impact of combined hormonal contraceptives containing estradiol","volume":"12","author":"Grandi","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.contraception.2021.01.001_bib0006","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2016.06.010","article-title":"Impact of estrogen type on cardiovascular safety of combined oral contraceptives","volume":"94","author":"Dinger","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2021.01.001_bib0007","first-page":"315","article-title":"Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism","volume":"10","author":"Bastianelli","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.contraception.2021.01.001_bib0008","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jsbmb.2008.03.027","article-title":"Estetrol: a unique steroid in human pregnancy","volume":"110","author":"Holinka","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.contraception.2021.01.001_bib0009","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.contraception.2016.04.015","article-title":"Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA)","volume":"94","author":"Apter","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2021.01.001_bib0010","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/GME.0000000000001561","article-title":"A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety","volume":"27","author":"Gaspard","year":"2020","journal-title":"Menopause"},{"key":"10.1016\/j.contraception.2021.01.001_bib0011","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1093\/carcin\/bgu144","article-title":"Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer","volume":"35","author":"Singer","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.contraception.2021.01.001_bib0012","first-page":"476","article-title":"Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: results of a phase II dose-finding pilot study","volume":"20","author":"Duijkers","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2021.01.001_bib0013","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/13625187.2017.1336532","article-title":"Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control","volume":"22","author":"Apter","year":"2017","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2021.01.001_bib0014","first-page":"463","article-title":"Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives","volume":"20","author":"Mawet","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2021.01.001_bib0015","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.contraception.2016.08.018","article-title":"Reduced haemostatic effects with drospirenone-based oral contraceptives containing estetrol versus ethinyl estradiol","volume":"95","author":"Kluft","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2021.01.001_bib0016","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/GME.0000000000000823","article-title":"Pharmacodynamic effects of the fetal estrogen estetrol in postmenopausal women: results from a multiple-rising-dose study","volume":"24","author":"Coelingh Bennink","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.contraception.2021.01.001_bib0017","unstructured":"EudraCT 2016-004267-40. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004267-40\/results (accessed on November 24, 2020)."},{"key":"10.1016\/j.contraception.2021.01.001_bib0018","unstructured":"E4FREEDOM EU\/Russia Study. ClinicalTrials.gov NCT02817828). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02817828?term=estetrol&phase=2&draw=2&rank=3 (accessed on November 24, 2020)."},{"key":"10.1016\/j.contraception.2021.01.001_bib0019","unstructured":"E4FREEDOM United States\/Canada Study (ClinicalTrials.gov NCT02817841) https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02817841?term=estetrol&phase=2&draw=2&rank=4 (accessed on November 24, 2020)."},{"issue":"suppl 1","key":"10.1016\/j.contraception.2021.01.001_bib0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/13697130701851814","article-title":"Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells","volume":"11","author":"Hammond","year":"2008","journal-title":"Climacteric"},{"key":"10.1016\/j.contraception.2021.01.001_bib0021","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","article-title":"Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters","volume":"102","author":"Douxfils","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2021.01.001_bib0022","first-page":"49","article-title":"The effect of dose-reduced combination oral contraceptives containing 20 \u00b5g of ethinyl estradiol and 100 \u00b5g of levonorgestrel on lipid metabolism: A meta-analysis","volume":"4","author":"Chen","year":"2016","journal-title":"Am J Intern Med"},{"key":"10.1016\/j.contraception.2021.01.001_bib0023","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJM199011153232003","article-title":"The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism","volume":"323","author":"Godsland","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2021.01.001_bib0024","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11154-011-9182-4","article-title":"Metabolic effects of contraceptive steroids","volume":"12","author":"Sitruk-Ware","year":"2011","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.contraception.2021.01.001_bib0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.beem.2012.09.004","article-title":"Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills","volume":"27","author":"Sitruk-Ware","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2021.01.001_bib0026","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.contraception.2004.12.005","article-title":"Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism","volume":"71","author":"Klipping","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2021.01.001_bib0027","first-page":"85","article-title":"Safety, efficacy, actions, and patient acceptability of drospirenone\/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder","volume":"1","author":"Breech","year":"2010","journal-title":"Int J Womens Health"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782421000020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782421000020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:57:33Z","timestamp":1769763453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782421000020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0010782421000020"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2021.01.001","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2021.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}